by Rod Raynovich | Jul 29, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, BIOgraph
It was a tough week in Life Science Tools and Diagnostics with many crosscurrents: debt ceiling uncertainty, earnings shortfalls, lackluster economic data and European debt crisis. The usual positive buzz from the AACC offered little support. We will provide an...
by Rod Raynovich | Jul 28, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Rayno Life Science Portfolio Recovers Up 1.73%; Jobless Claims Help The thrashing of Illumina (ILMN) yesterday appears to be overdone as the stock is recovering to the $60 area on volume of over 3.5M shares as of mid-day trading.The Tools and Diagnostics sector is...
by Rod Raynovich | Jul 19, 2011 | 2024-25 Life Science Portfolios, Macro
Life Science Stocks Follow NASDAQ Up: EXAS, MITI, REGN Soar Large healthcare companies report over next two weeks Stocks roared today on IBM earnings last night, debt ceiling negotiation progress with bipartisan Senators,and surge in housing starts. AAPL piled on...
by Rod Raynovich | Jul 19, 2011 | 2024-25 Life Science Portfolios, Macro
With the QQQ you are still Bullish on Biotech We mentioned yesterday that those wanting to be bullish large cap NASDAQ stocks but remain bullish on biotech would be better off with a QQQ position as pure play biotechs are due for a rest. Today the QQQ is up 1.69%...
by Rod Raynovich | Jul 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Todays’ Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate support of 100.The healthcare sector overall was down 0.88%...
by Rod Raynovich | Jul 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph, Reading List
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom about European debt, US debt ceiling and potential default. JPMorgan...
by Rod Raynovich | Jul 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by...
by Rod Raynovich | Jul 5, 2011 | 2024-25 Life Science Portfolios
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in April 2010 at a price of $20.
by Rod Raynovich | Jun 26, 2011 | 2024-25 Life Science Portfolios, BIOgraph
We will be attending the BIO Meeting in Washington DC and will not be posting as usual. Note that there were two news items over the weekend on our portfolio stocks: A positive article on Gilead (GILD) in Barron’s. Gilead Sciences Shares Could Rally –...
by Rod Raynovich | Jun 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The market touched the March lows last Friday , down for the year, and buyers swarmed in.Biotechs were strong yesterday buffering tech weakness and today the baton was passed to several sectors with a broad rally especially with NASDAQ up 2.23%. The NASDAQ-100 qqq...
